Extracellular vesicles as mediators of alloimmunity and their therapeutic potential in liver transplantation

doi:10.5500/wjt.v10.i11.330

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5517)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

383

WORD

177

HTML

2558

Figures (1-4)

532

Tables (1-1)

204

Sum=3854

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

601

Download

1062

Sum=1663

Nov 28, 2020 (publication date) through May 11, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Transplant. Nov 28, 2020; 10(11): 330-344
Published online Nov 28, 2020. doi: 10.5500/wjt.v10.i11.330

Table 1 Clinical trials of engineered extracellular vesicle-based therapies

Treatment target	Trial phase	Source of EVs	EV manipulation	Results
Pancreatic cancer (NCT03608631)	Phase I	MSC, allogeneic	siRNA direct loading	Not yet recruiting
Colon cancer[72]	Phase I	Plant origin	Curcumin direct loading	Active
Melanoma[73]	Phase I	Immature DCs, autologous	Tumor antigen (peptide) direct loading	Safe, well tolerated, mixed responses.
Non-small cell lung cancer (NCT01159288)	Phase II	Mature DCs, autologous	Tumor antigen (peptide) direct loading	Safe, well tolerated, mixed responses.
Non-small cell lung cancer[74]	Phase I	Immature DCs, autologous	Tumor antigen (peptide) direct loading	Safe, well tolerated, mixed responses.
Malignant ascites (NCT01854866)	Phase II	Tumor derived	Chemotherapeutic agent loading	Unknown
Acute ischaemic stroke (NCT03384433)	Phase I/II	MSCs, allogeneic	miRNA loading	Completed

EVs: Extracellular vesicles; MSC: Mesenchymal stem cell; DCs: Dendritic cells.

Citation: Mastoridis S, Martinez-Llordella M, Sanchez-Fueyo A. Extracellular vesicles as mediators of alloimmunity and their therapeutic potential in liver transplantation. World J Transplant 2020; 10(11): 330-344
URL: https://www.wjgnet.com/2220-3230/full/v10/i11/330.htm
DOI: https://dx.doi.org/10.5500/wjt.v10.i11.330